Anemia and red blood cell transfusion in critically ill cardiac patients

Red blood cell (RBC) transfusion is common in critically ill adults and children [1‐3]. Patients with cardiac disease are transfused at higher hemoglobin (Hb) thresholds than those with non-cardiac illness [1‐3]. Both anemia and RBC transfusion are associated with increased mortality in cardiac patients. The risk/benefit balance of RBC transfusion in critically ill cardiac patients is currently a matter of debate.

This narrative review critically appraises the available data on the relationship between anemia, RBC transfusion and outcome of critically ill adults and children with cardiac disease. We discuss the prevalence and risks of anemia in the ICU, the rationale for RBC transfusion, the evidence supporting restrictive transfusion strategies, and the growing interest in goal-directed transfusion therapy. Premature infants and intraoperative transfusions will not be addressed in this paper, nor will a detailed discussion of the relationship between length of storage of RBC units and outcomes, since the latter is discussed in other papers [4‐7].

The prevalence of anemia in adults with heart failure ranges from 18 to 38% [8]; it was 19.1% in 27 observational studies indexed before July 2011 that enrolled 233,144 patients with acute coronary syndrome [9]. Anemia may result in insufficient oxygen delivery (DO₂) to vital organs and tissues if DO₂ drops below a critical DO₂ (Figure 1). DO₂ is determined by cardiac output (Q’) and arterial content in:

DO₂ = Q’ × CaO₂

and CaO₂ = {(Hb × SaO₂ × 1.39) + (PaO₂ × 0.0031)} [10]

Any drop of the Hb level decreases CaO₂ and DO₂ if the compensatory increase of Q’ is not high enough. Anemia may be poorly tolerated by patients with cardiac failure and/or coronary disease because their ability to increase cardiac output to compensate for anemia is limited [11, 12].

Carson et al. [13] studied the association between anemia and surgical mortality in 1,958 Jehovah’s Witness patients with cardiovascular disease who refused transfusion; the risk of mortality was inversely related to Hb level (Figure 2). Table 1 summarizes the results of two meta-analyses [9, 14] and six observational studies [15‐20] on the relationship in cardiac adults between anemia and adverse outcomes; a statistically significant association is reported in almost each instance. However, it must be underlined that the relationship between anemia and outcome is fundamentally confounded in all these studies by co-morbidities that might have caused the anemia (renal failure, gastro-intestinal bleeding, iron deficiency, and so on).

A number of host characteristics specific to children, like growth, fetal Hb, different cardiac diseases and physiology, may impair their adaptive mechanisms to anemia. There are few data on the relationship between anemia and outcomes in cardiac children. Kammache et al. [21] reported some anemia (Hb < 100 g/L) in 24% of 218 children with idiopathic dilated cardiomyopathy; mortality was more frequent in anemic children.

In the United States, 7.8% to 92.8% of adults undergoing cardiac surgery are transfused [22‐24]. A transfusion is given after cardiac surgery in 38% to 74% of children [3, 25‐28].

RBC transfusions are sometimes given to cardiac patients to rapidly replace blood volume in cases of postoperative blood losses [29]. In the absence of active bleeding, some practitioners declare that low Hb concentration and/or signs of inadequate DO₂ (low central venous O₂ saturation (ScvO₂), high lactate level, low SaO₂/FiO₂ ratio) would prompt them to prescribe RBC transfusions in this population [29]. There is no doubt that Hb level is a very important determinant of RBC transfusions in critically ill patients [30‐32]. However, there are data suggesting that Hb level is not the only determinant of RBC transfusions in cardiac patients. In a retrospective study on transfusions in pediatric cardiac ICU [24], admission Hb ranged from 141 to 150 g/L, nadir Hb level was 121 g/L in patients who were not transfused, 119 g/L in a low transfusion group, and 115 g/L in a high transfusion group, suggesting that transfusions may have been given for reasons other than anemia. Age below one year, low weight, high severity of illness as measured by the acute physiology and chronic health evaluation (APACHE) or pediatric risk of mortality (PRISM) score, cardiopulmonary bypass, cyanotic heart condition and lower admission Hb level are also reported to be independently associated with increased administration of RBC transfusions [24, 33].

RBC transfusion should be given only when the risk/benefit ratio is favorable (ratio < 1). The threshold at which the risks of anemia outweigh the risks of transfusion is currently unknown.

There are little available hard data on the clinical benefits of RBC transfusion. In a prospective study that enrolled 303 Kenyan children with Hb below 50 g/L at hospitalization, 116 (38%) did not receive a transfusion, mostly because of blood unavailability, while 187 did; the mortality was significantly higher in non-transfused children (41.4% versus 21.4%, P < 0.001) [34]. This study suggests that RBC transfusion may improve the survival of anemic hospitalized patients with Hb level below 50 g/L, but what threshold above 50 g/L should be used to prescribe a RBC transfusion in cardiac patients remains a matter of debate.

The available evidence suggests that RBC transfusion in patients with cardiac disease is an independent risk factor of mortality (Table 2).

Three studies reported some transfusion benefits if the Hb level is low (<80 g/L), but they also reported harm with high Hb level [35, 36, 46]. A retrospective descriptive epidemiological study of 78,974 patients older than 65 years with acute myocardial infarction showed that RBC transfusion was associated with a lower risk of 30-day mortality if hematocrit was below 24% (odds ratio (OR): 0.22; 95% CI: 0.11 to 0.45) or between 30% and 33% (OR: 0.69; 95% CI: 0.53 to 0.89), but not in cardiac patients with hematocrit above 33% [46]. Alexander et al. [35] reported that RBC transfusion tended to have a beneficial impact on mortality if the nadir hematocrit was ≤ 24% (adjusted odds ratio (aOR): 0.68; 95% CI: 0.45 to 1.02), but the opposite was found if it was > 30% (aOR: 3.47; 95% CI: 2.30 to 5.23). Aronson et al. [36] reported that RBC transfusion in patients with myocardial infarction decreased the risk of mortality if the pre-transfusion Hb level was ≤ 80 g/L (adjusted hazard ratio (aHR): 0.13: 95% CI: 0.03 to 0.65), but the risk was increased if the Hb level was > 80 g/L (aHR: 2.2; 95% CI: 1.5 to 3.3). Shehata et al. [19] reported a lower risk of mortality in 2,102 adults who were transfused after coronary artery bypass graft (CABG), but the association was not statistically significant (adjusted OR (aOR) = 0.44; 95% CI: 0.32 to 14.1).

On the other hand, six studies of adults undergoing cardiac surgery, CABG or with myocardial infarction reported increased mortality in transfused cardiac patients [39, 40, 42‐44, 47]. Rao et al. [43] published a descriptive epidemiological study on 24,112 patients with acute coronary syndrome who were enrolled in three large randomized controlled trials (RCTs). They compared the outcomes of those who received at least one RBC transfusion (n = 21,711) and those who did not (n = 2,401); RBC transfusion was associated with an increased HR for 30-day mortality (HR = 3.94; 95% CI: 3.26 to 4.75). Probability of 30-day mortality was higher in transfused patients with nadir hematocrit values above 25%. In the systematic review of Chatterjee et al. [51], the risk ratio of death in transfused patients versus controls was 2.91 (95% CI: 2.46 to 3.44) and the risk of secondary myocardial infarction was 2.04 (95% CI: 1.06 to 3.93), but there was a very significant heterogeneity in both instances (I ² : 92% and 98% respectively). Garfinkle et al. [53] also published a systematic review on 11 observational studies that enrolled 290,847 patients with acute coronary syndrome: the unadjusted OR of mortality in transfused patients ranged from 1.9 to 11.2; a meta-analysis was not performed because there was too much heterogeneity, but the data suggested a protective effect of RBC transfusion if nadir Hb drops below 80 g/L and neutral or harmful effects above 110 g/L. In summary, there is evidence in adults with cardiac disease that RBC transfusion is associated with mortality and ischemic events.

There is less evidence in children. Three studies reported prolonged length of mechanical ventilation in children who received RBC transfusion after cardiac surgery [48, 49, 54], three reported prolonged length of PICU and/or hospital stay [24, 49, 54] and three reported an increased incidence of infections [33, 50, 54]. In 657 consecutive children undergoing open heart surgery, Székely et al. [33] found an association between total volume of blood transfusion and the rate of infections (aOR: 1.01; 95% CI: 1.002 to 1.02, P < 0.01), but no association with mortality (aOR: 1.00; 95% CI: 0.99 to 1.02, P = 0.65).

Is it justified to prescribe more RBC transfusions to cardiac than to non-cardiac ICU patients? The available data on this question are inconclusive: while some descriptive studies suggest a benefit to transfusion, most studies associate RBC transfusion to worse outcomes. Descriptive studies cannot prove that there is a cause-effect relationship between a risk factor and a given outcome: adjustment for confounders like volume of RBC transfusion and administration of other blood products can be done, but a possibility always remains that unknown confounders play a role. Moreover, severity of illness is associated with both transfusion and mortality [8, 24]. A multivariate analysis cannot deconstruct such confounding by indication [55]; only RCTs can [56].

The safety of blood products with respect to transfusion-transmitted infectious diseases has improved greatly in recent decades. Presently, the greatest concern is non-infectious serious hazards of transfusion (NISHOT) [57‐59].

NISHOT may be non-immune or immune-mediated. Short-term non-immune NISHOT include transfusion-related circulatory overload (TACO) and overtransfusion. Overtransfusion is of concern because of the risk of TACO and/or hyperviscosity. Viscous blood flow may impair DO₂ in small vessels and decrease coronary blood flow. Barr et al. [60] reviewed the data of 1,474 transfused patients: 19% of them were overtransfused according to the British RBC transfusion guidelines. Sabatine et al. [61] reported an increased mortality in patients with ST-elevation myocardial infarction when Hb value was > 170 g/L (OR = 1.79; 95% CI: 1.18 to 2.71, P = 0.007) and > 160 g/L (OR = 1.31; 95% CI: 1.03 to 1.66, P = 0.027) in patients with non-ST-elevation myocardial infarction.

Immune-mediated NISHOT include hemolytic and allergic reactions, transfusion-related immunomodulation (TRIM), transfusion-related acute lung injury (TRALI), nosocomial infections, transfusion-associated graft versus host disease, and alloimmunization to RBC and HLA antigens [57, 62, 63].

In critically ill cardiac patients, TRIM may represent a significant ‘second-hit’ when added to pre-existing organ dysfunction and/or a systemic inflammatory response syndrome (SIRS), which may result in TRALI and multiple organ dysfunction syndrome. Vlaar et al. [64] reported that in cardiac surgery patients, RBC transfusion was associated with an increase pulmonary leak index, an early marker of acute lung injury. Inflammatory markers in bronchoalveolar lavage were increased in transfused cardiac surgery patients when compared to controls [65]. TRALI may be an important underdiagnosed cause of lung injury in cardiac and non-cardiac ICU patients [66, 67].

Although NISHOT are currently the most important causes of transfusion-related fatalities, their incidence rate in cardiac patients is not well characterized [58].

As illustrated in Figure 1, the relationship between DO₂ and O₂ consumption (VO₂) remains horizontal as long as compensatory mechanisms (increasing cardiac output and O₂ extraction) are still effective [10, 68]. However, VO₂ drops with DO₂ below a critical threshold. Anemia decreases DO₂ and it is unmistakably deleterious below a certain threshold. The critical Hb level threshold below which DO₂ becomes significantly impaired and transfusion becomes less harmful than persisting anemia is unknown and likely varies depending upon the underlying condition and clinical status of each patient. Anemia is well endured by healthy subjects: acute isovolemic reduction of Hb level down to 50 g/L was hemodynamically well tolerated by 11 resting healthy humans [69], but delayed memory was observed in 31 healthy young volunteers after a similar reduction of Hb [70]. However, cardiac patients may have higher thresholds of critical DO₂ than healthy adults and target Hb for transfusion might be different (Figures 1 and 2). Moreover, patients with cardiac disease may also be more vulnerable than the general population to adverse effects of transfusion (disturbed rheology [71] and coagulation [65], NISHOT [57], dysfunctional vasoregulation [72], circulatory overload, and so on).

Confronted with the risks of transfusion and a growing body of literature associating RBC transfusion with adverse outcomes, a number of RCTs have now compared the safety of adopting a restrictive versus liberal RBC transfusion strategy (low versus higher threshold Hb) in critically ill patients with cardiac disease (Table 3).

We found seven RCTs conducted in adults with cardiac illness [19, 23, 52, 73‐76]; all enrolled only hemodynamically stable patients. All but one [23] reported that a restrictive strategy was as safe or safer than a liberal strategy. Three RCTs included more than 50 patients.

In 1999, Hébert et al. [80] published the ‘Transfusion Requirements in Critical Care’ (TRICC) study. Euvolemic patients were randomized to receive a RBC transfusion if Hb level was below 100 g/L (liberal strategy) or below 70 g/L (restrictive strategy). Patients with acute myocardial infarction and unstable angina were excluded. A subgroup analysis of 357 patients with cardiovascular disease was published in 2001 [75]; the 30-day all-cause mortality was similar (22.5% versus 22.7%, P = 1.00).

Hajjar et al. [23] published a single center non-inferiority RCT of 502 adults undergoing cardiac surgery who were allocated to receive a transfusion if hematocrit was below 24% or 30%. The pre-transfusion Hb level was 91 in the restrictive and 105 g/L in the liberal group. They found a similar incidence of 30-day all-cause mortality (6% in the restrictive and 5% in the liberal group, P = 0.93), cardiogenic shock (5% versus 9%, P = 0.42), acute respiratory distress syndrome (1% versus 2%, P = 0.99) and acute renal failure (5% versus 4%, P = 0.99). The number of RBC units transfused was independently associated with 30-day all-cause mortality (HR = 1.2/unit; 95% CI: 1.1 to 1.4, P = 0.002).

Carson et al. [74] published the ‘Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair’ (FOCUS) study, a large multicenter RCT of 2,016 adults over 50 years of age with known atherosclerotic disease undergoing a hip surgery and who had a Hb level below 100 g/L within 3 days post-surgery. The restrictive group was transfused if Hb level fell below 80 g/L, the liberal group if below 100 g/L. Primary outcome was ability to walk 10 feet unassisted or death 60 days post-randomization. No difference was found in any of the outcomes, including survival, postoperative complications, activities of daily living and disposition.

In summary, the available RCTs suggest that a restrictive transfusion strategy (threshold Hb level for transfusion: 70 or 80 g/L) appears as safe as a liberal strategy in stable adult ICU patients with cardiac disease.

Three RCTs compared a restrictive and a liberal transfusion strategy after pediatric cardiac surgery.

In the ‘Transfusion Requirements In PICU’ (TRIPICU) study [81], 637 stabilized critically ill children were randomized to receive a RBC transfusion if their Hb dropped below 70 or 95 g/L [81]. Patients were considered stable if mean systemic arterial pressure was not less than two standard deviations below the normal mean for age and if cardiovascular treatment (fluids and/or medication) had not been increased for at least two hours before enrollment. Children with cyanotic cardiac disease and neonates under 28 days were excluded. A sub-group analysis of 125 cardiac children enrolled in TRIPICU demonstrated no significant difference in new or progressive multiple organ dysfunction syndrome (restrictive versus liberal group: 12.7% versus 6.5%, P = 0.36), PICU length of stay (7.0 ± 5.0 versus 7.4 ± 6.4 days) or 28-day mortality (3.2% versus 3.2%) [79].

An RCT compared the outcome of cardiac children older than 6 weeks randomized to receive a RBC transfusion if Hb level dropped below 80 g/L or 108 g/L [78]. Patients with cyanotic cardiac disease were excluded. Randomization occurred before surgery; the research protocol with respect to RBC transfusion was initiated in the operating room and maintained up to PICU discharge. One hundred patients were enrolled and retained for analysis. Duration of mechanical ventilation, length of PICU stay and incidence of adverse events were similar in both groups, but length of hospital stay was shorter in the restrictive group (median: 8 {interquartile range: 7 to 11} versus 9 {7 to 14} days, P = 0.063).

Physicians target higher Hb values for critically ill children with cyanotic heart disease [28, 29]. In an RCT completed by Cholette et al. [77], 60 children were randomized after Glenn or Fontan palliation to a restrictive (transfusion if Hb < 90 g/L) or liberal group (<130 g/L). One death was observed (liberal group). There was no difference in mean and peak arterial lactate, arterio-venous and arterio-cerebral oxygen content. Although not powered to demonstrate statistical significance, mortality, PICU and hospital length of stay, duration of mechanical ventilation, dose and duration of inotropic support were similar.

Goal-directed RBC transfusion therapy targeting a physiological goal may be a more appropriate target than specific Hb levels. The concept of goal-directed therapy is well illustrated by the RCT conducted by Rivers et al. [82]: 266 adults with severe sepsis or septic shock were randomized to be monitored or not with ScvO₂. Patients allocated to ScvO₂ monitoring were also assigned to a bundle of treatment to maintain their ScvO₂ over 70%; this bundle included, in sequential order, mechanical ventilation, fluid bolus, vasoactive drugs and RBC transfusion if the ScvO₂ remained under 70% after all other interventions. Mortality was 30.5% with goal-directed therapy versus 46.5% in controls.

There are currently no hard data on goal-directed transfusion therapy in cardiac patients. Goals that can be considered include physiologic parameters like DO₂ measured by a Swan-Ganz catheter or locally with near infrared spectroscopy (NIRS), global oxygen consumption (VO₂), blood lactate, mixed venous O₂ saturation (Sv’O₂), ScvO₂, tissue O₂ saturation and O₂ extraction rate [10]. Well-conducted research is required to demonstrate the reliability and clinical applicability of a test before we start to use it at the bedside. There are examples of tests that were too rapidly adopted by the medical community. For example, regional (splanchnic and/or renal) NIRS is frequently used to detect low cardiac output in ICU patients; a recent study showed that its positive predictive value is so low that it cannot be considered a reliable test [83]. Repeated (‘dynamic’) measurements of NIRS might be more informative than ‘static’ measures [84], but this remains to be proven. Transfusion therapy guided by ScvO₂ is another candidate. The results of the trial by Rivers et al. [82] suggested that RBC transfusion might be useful in septic patients. Another RCT conducted in 102 children with severe sepsis or fluid refractory shock reported similar results (mortality: 11.8% versus 39.2% in controls) [85]. However, in the ProCESS three arms RCT [86], 1,341 adults were allocated to a protocol-based goal-directed therapy that required the placement of a central venous catheter, a protocol-based standard therapy without such catheter, or usual care; no difference was observed in any outcomes, which questions the results of the RCTs by Rivers and de Oliveira [82, 85]. Moreover, the specific contribution of RBC transfusions was unclear in these RCTs and none enrolled cardiac patients.

Currently, we do not know what physiologic parameters we must use to guide a goal-directed transfusion therapy in cardiac patients. Further clinical studies are required before a given goal that would help practitioners to precisely decide when to transfuse cardiac patients can be recommended in this population.